Beximco Pharmaceuticals PLC (DHA:BXPHARMA) Stock Price, Trades & News

Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	1.64
Equity-to-Asset	0.76
Debt-to-Equity	0.05
Debt-to-EBITDA	0.24
Interest Coverage	16.87
Piotroski F-Score	N/A/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.06	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12.3
	3-Year EBITDA Growth Rate	8.9
	3-Year EPS without NRI Growth Rate	10.3
	3-Year FCF Growth Rate	22.6
	3-Year Book Growth Rate	9.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	17.15
	Future 3-5Y Total Revenue Growth Rate Estimate	11.33

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	60.14
	9-Day RSI	56.87
	14-Day RSI	59.12
	3-1 Month Momentum %	22.47
	6-1 Month Momentum %	22.05
	12-1 Month Momentum %	30.55

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.13
	Quick Ratio	1.89
	Cash Ratio	0.76
	Days Inventory	198.08
	Days Sales Outstanding	24.54
	Days Payable	30.34

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Dividend Growth Rate	4.6
	Forward Dividend Yield %	3.15
	Shareholder Yield %	2.05

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	47.86
	Operating Margin %	21.31
	Net Margin %	16.04
	EBITDA Margin %	24.46
	FCF Margin %	2.57
	OCF Margin %	9.23
	ROE %	15.28
	ROA %	11.27
	ROIC %	12.9
	3-Year ROIIC %	51.37
	ROC (Joel Greenblatt) %	19.52
	ROCE %	17.47
	Years of Profitability over Past 10-Year	9

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	7.58
	Forward PE Ratio	7.06
	PE Ratio without NRI	7.6
	Shiller PE Ratio	12.23
	Price-to-Owner-Earnings	9.97
	PEG Ratio	0.53
	PS Ratio	1.22
	PB Ratio	1.09
	Price-to-Tangible-Book	1.23
	Price-to-Free-Cash-Flow	47.32
	Price-to-Operating-Cash-Flow	13.18
	EV-to-EBIT	6.15
	EV-to-Forward-EBIT	869.31
	EV-to-EBITDA	5.6
	EV-to-Forward-EBITDA	4.61
	EV-to-Revenue	1.36
	EV-to-Forward-Revenue	1.13
	EV-to-FCF	52.26
	Price-to-GF-Value	1.18
	Price-to-Projected-FCF	0.98
	Price-to-Median-PS-Value	0.69
	Price-to-Peter-Lynch-Fair-Value	0.68
	Price-to-Graham-Number	0.65
	Price-to-Net-Current-Asset-Value	7.18
	Earnings Yield (Greenblatt) %	16.28
	FCF Yield %	2.06
	Forward Rate of Return (Yacktman) %	13.4

Financials (Next Earnings Date:2026-08-28 Est.)

Annual Quarterly TTM

DHA:BXPHARMA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Beximco Pharmaceuticals PLC Executives

Details

GF Value™: BDT128.18

DHA:BXPHARMA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with BXPHARMA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil BDT)	53,926.357
	EPS (TTM) (BDT)	19.39
	Beta	-
	3-Year Sharpe Ratio	0.06
	3-Year Sortino Ratio	0.09
	Volatility %	38.81
	14-Day RSI	59.12
	14-Day ATR (BDT)	3.659168
	20-Day SMA (BDT)	151.125
	12-1 Month Momentum %	30.55
	52-Week Range (BDT)	99.5 - 158.5
	Shares Outstanding (Mil)	446.11

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	9999
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Beximco Pharmaceuticals PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Beximco Pharmaceuticals PLC Stock Events

Financials Calendars

Event	Date	Price (BDT)
First quarter earnings results for 2027	2026-11-30	In 120 days
General meeting for 2026	2026-10-07	In 66 days
Fourth quarter earnings results for 2026	2026-08-28	In 26 days
BDT 4.750000 Cash Dividend	2026-08-03	In 1 day
Annual report for 2025	2026-08-03	In 1 day
First quarter earnings results for 2026	2026-06-24	143.00 (+0.00%)
Fourth quarter earnings results for 2025	2026-06-24	143.00 (+0.00%)
Second quarter earnings results for 2026	2026-06-24	143.00 (+0.00%)
Third quarter earnings results for 2025	2026-06-24	143.00 (+0.00%)
Second quarter earnings results for 2025	2025-01-27	75.10 (-4.21%)

Show

Entries

Beximco Pharmaceuticals PLC Frequently Asked Questions

What is Beximco Pharmaceuticals PLC(DHA:BXPHARMA)'s stock price today?

The current price of DHA:BXPHARMA is BDT150.90. The 52 week high of DHA:BXPHARMA is BDT158.50 and 52 week low is BDT99.50.

When is next earnings date of Beximco Pharmaceuticals PLC(DHA:BXPHARMA)?

The next earnings date of Beximco Pharmaceuticals PLC(DHA:BXPHARMA) is 2026-08-28 Est..

Does Beximco Pharmaceuticals PLC(DHA:BXPHARMA) pay dividends? If so, how much?

Beximco Pharmaceuticals PLC(DHA:BXPHARMA) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Articles on Beximco Pharmaceuticals PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.